Table 2.
Relationship between Various Clinicopathological Factors and the Combined Expression of u-PA and u-PAR Protein in Cancer Cells and Fibroblasts
| Characteristics | Group A | Group B | Group C |
|---|---|---|---|
| Neoplastic cells | |||
| u-PA staining | + | − | − |
| u-PAR staining | − | + | − |
| Fibroblasts | |||
| u-PA staining | − | + | − |
| u-PAR staining | − | − | − |
| No. of patients | 11 | 12 | 23 |
| T category* | |||
| pT1, pT2 | 2‡ | 6 | 13 |
| pT3, pT4 | 9 | 6 | 10 |
| N category* | |||
| pN0 | 1§ | 4 | 12 |
| pN1 | 10 | 8 | 11 |
| Lymphatic invasion* | |||
| Negative | 1 | 1 | 7 |
| Positive | 10 | 11 | 16 |
| Vascular invasion* | |||
| Negative | 4 | 6 | 14 |
| Positive | 7 | 6 | 9 |
| Prospective hepatic metastases† | |||
| Negative | 8 | 11 | 22 |
| Positive | 3 | 1 | 1 |
| Prospective distant metastasis† | |||
| Negative | 0¶∥ | 11 | 22 |
| Positive | 11 | 1 | 1 |
*At operation.
†During the period of follow-up.
‡P < 0.05, Group A versus C.
§P < 0.05, Group A versus C.
¶P < 0.001, Group A versus B.
∥P < 0.001, Group A versus C.